Qu Biologics to Receive $6.7 Million in IRAP Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly. Vancouver, BC, October 27, 2022--Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, announced that it is receiving advisory services and research and development funding of up to $6,659,050 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).